历年净利、扣非情况(亿元) 1 (亿元) 0.148 0 -0.34 -1.27 -1.56 -1 -2.05 -3.48 -2 -3 -4 2020 2021 2023 2022 2024 2025E 归母净利润 扣非净利润 制图数据来自恒生聚源数据库 历年净利、扣非同比增长情况(%) 500 55-16 --- 31:15 -- 0 38.01 % -335.33 -266.19'-173.61 -500 2021 2020 2022 2023 2024 2025E ¬○- 归母净利润同比增长率 -○- 扣非净利润同比增长率 中证智能财讯广生堂（300436）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润亏损1.7亿元至2.4亿元，上年同期亏损1.56亿元；扣非净利润亏 损1.78亿元至2.48亿元，上年同期亏损2亿元。以最新收盘价计算，市净率（LF）约41.43倍，市销率（TTM）约36.83倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司秉承"广播仁爱·关注民生"的企业使命，坚定为人类的肝脏健康提供科学解决方案的梦想，坚定不移推动创新药物研发，实 ...

报告期内，公司归属于上市公司股东的净利润同比有所下降，主要是去年同期存在超过人民币3.5亿元 的一次性投资收益(非经常性损益)，从而形成了较高的基数。此外，报告期内本公司旗下联营公司因研 发进展未达预期，预计将对本集团净利润造成一定影响，具体影响以会计师事务所最终确认为准。 报告期内，本公司归属于上市公司股东的扣除非经常性损益的净利润较去年同期实现增长，主要是主营 业务收入与利润的稳步提升。同时，本公司持续通过强化财务管理及优化资源分配，进一步提升营运效 率，推动盈利能力的持续改善。尽管联营公司预计将对本集团扣除非经常性损益后的净利润产生一定影 响，但本集团仍实现了扣除非经常性损益后净利润的稳健增长，展现出主营业务的经营韧性与持续增长 能力。 智通财经APP讯，海普瑞(09989)发布公告，该公司预计截至2025年12月31日止年度归属于上市公司股东 的净利润人民币2.84亿元-人民币3.77亿元，同比下降41.71%-56.09%。 报告期内，本集团在全球肝素制剂市场业务拓展成果显著，各区域销售表现稳步向上，市场占有率持续 提升，依诺肝素制剂销量取得两位数增长，进一步巩固了本集团的全球竞争地位。 ...

南财智讯1月30日电，天宇股份发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 1.20亿元—1.60亿元，同比预增114.53%—186.05%；预计2025年全年归属于上市公司股东的扣除非经常 性损益的净利润为1.12亿元—1.52亿元，同比预增66.03%—125.32%。报告期内，公司业绩实现显著增 长，主要驱动因素包括：公司积极把握市场机遇，持续拓宽客户渠道并加强精细化管理，企业核心竞争 力得到进一步加强；主营业务拓展方面，通过优化产品结构、完善市场布局及加强成本管控等措施，有 效提升了公司非沙坦类业务及制剂业务的营收规模和毛利增长；公司通过大幅缩减外汇衍生品交易规模 有效降低损失。报告期内公司预计非经常性损益影响归属于上市公司的净利润金额约800万元，主要系 政府补助。 ...

Core Viewpoint - Haizheng Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses for the company [1] - The transition of construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

Core Viewpoint - Haizheng Biomedical Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in higher depreciation and tax expenses, further squeezing profits for the period [1]

Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range of 27.2 million to 39.3 million yuan, representing a year-on-year decrease of 35% to 55% due to increased expenses in various areas [1] Financial Performance - The anticipated decline in net profit is attributed to increased sales expenses from intensified efforts in the formulation market [1] - Management expenses have risen due to payments related to restructuring and intermediary fees [1] - Research and development expenses have increased as the company continues to invest in new product development and improve its R&D management system [1] - Other income has decreased due to a reduction in government subsidies related to daily operations [1] - The company has conducted a comprehensive review of its receivables and other assets, leading to an increase in asset impairment losses as it prepares for potential write-downs [1]

Group 1 - The company Jin Cheng Pharmaceutical announced on January 30 that it has recognized an asset impairment provision totaling 55.6624 million yuan, which will be included in the company's 2025 financial results [1] - This impairment is expected to reduce the net profit attributable to shareholders of the listed company by approximately 49.6106 million yuan for the year 2025 [1] - The total equity attributable to shareholders of the listed company will also decrease by about 49.6106 million yuan [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers reportedly busy with orders scheduled until 2028 [1] - Employees are working in three shifts, and production lines are operating 24 hours a day to meet the high demand [1]

南财智讯1月30日电，广生堂发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 亏损1.70亿元—2.40亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损 1.78亿元—2.48亿元。本报告期内，公司业绩亏损主要影响原因如下：1、报告期内，公司始终坚持创新 药发展战略，持续研发投入以快速推进创新药临床研究，且受前期固定资产投资较大等因素影响，公司 研发费用和管理费用保持在较高水平。截止目前，在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III 期临床试验已完成526例受试者入组，达到临床方案设定的计划目标入组数，后续将继续推进受试者入 组工作，预计于2026年2月中旬完成全部入组，最终入组人数可能在原计划目标基础上有少部分增加。 创新药研发周期长，投入大，风险高，容易受到多方面因素的影响，临床研究存在研究进度和结果不及 预期甚至失败的风险，后续能否获得批准存在不确定性。敬请广大投资者谨慎决策，注意防范投资风 险。2、公司基于谨慎性原则，对报告期末合并报表范围内无形资产、存货、固定资产等资产进行减值 测试，对发生减值的资产计提减值准备。3、报告期内，预计非经常 ...

Core Viewpoint - Jincheng Pharmaceutical has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expectations of a decrease of 73.07% to 79.67% year-on-year [1] Financial Performance Summary - The company anticipates a net profit attributable to shareholders of 40 million to 53 million yuan for 2025, which represents a substantial decrease compared to the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 28 million and 37 million yuan, reflecting a year-on-year decline of 79.43% to 84.44% [1] Reasons for Performance Change - The primary reasons for the decline in performance include: 1. A slowdown in product market demand, intense industry competition, and the impact of national centralized procurement policies, leading to a decrease in both prices and sales volume for certain products in the intermediate and formulation segments [1] 2. An increase in asset impairment provisions for 2025 compared to the previous year, in response to industry and market changes [1] 3. The need for the company's subsidiaries, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Guangdong Landu Pharmaceutical Co., Ltd., to pay back taxes from previous years [1] - The impact of non-recurring gains and losses on net profit is estimated to be between 12 million and 16 million yuan [1]

博瑞医药公告称，预计2025年年度归母净利润4130万元到6190万元，同比减少67.28%到78.17%；扣非 净利润430万元到2490万元，同比减少86.21%到97.62%。主要因流感趋势、竞争格局、客户需求变化致 营收和毛利减少，在建工程转固折旧增加，研发投入加大。公司在研项目进展多，如BGM0504注射液2 型糖尿病和减重两项适应症国内III期临床已完成入组；口服BGM0504片剂中美开展一期临床等。不过 创新药尚处早期，商业化存不确定性。 ...